🎉 M&A multiples are live!
Check it out!

Vitrolife Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vitrolife and similar public comparables like InfuSystem, Philips, and Myomo.

Vitrolife Overview

About Vitrolife

Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient’s fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.


Founded

1994

HQ

Sweden
Employees

1.1K+

Website

vitrolife.com

Financials

LTM Revenue $367M

LTM EBITDA $114M

EV

$2.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vitrolife Financials

As of September 2025, Vitrolife reported last 12-month revenue of $367M and EBITDA of $114M.

In the same period, Vitrolife generated $215M in LTM gross profit and $47.2M in net income.

See Vitrolife valuation multiples based on analyst estimates

Vitrolife P&L

In the most recent fiscal year, Vitrolife reported revenue of $380M and EBITDA of $128M.

Vitrolife expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vitrolife valuation multiples based on analyst estimates
LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $367M XXX $380M XXX XXX XXX
Gross Profit $215M XXX $225M XXX XXX XXX
Gross Margin 59% XXX 59% XXX XXX XXX
EBITDA $114M XXX $128M XXX XXX XXX
EBITDA Margin 31% XXX 34% XXX XXX XXX
EBIT $74.2M XXX $83.2M XXX XXX XXX
EBIT Margin 20% XXX 22% XXX XXX XXX
Net Profit $47.2M XXX $54.0M XXX XXX XXX
Net Margin 13% XXX 14% XXX XXX XXX
Net Debt XXX XXX $85.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vitrolife Stock Performance

Vitrolife has current market cap of SEK 19.8B (or $2.1B), and EV of SEK 20.8B (or $2.2B).

Market Cap Evolution

Vitrolife Stock Data

As of October 17, 2025, Vitrolife's stock price is SEK 146 (or $15).

See Vitrolife trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.2B $2.1B XXX XXX XXX XXX $0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Vitrolife Valuation Multiples

Vitrolife's trades at 5.8x EV/Revenue multiple, and 17.2x EV/EBITDA.

See valuation multiples for Vitrolife and 15K+ public comps

Vitrolife Financial Valuation Multiples

As of October 17, 2025, Vitrolife has market cap of $2.1B and EV of $2.2B.

Equity research analysts estimate Vitrolife's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Vitrolife has a P/E ratio of 44.1x.

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $2.1B XXX $2.1B XXX XXX XXX
EV (current) $2.2B XXX $2.2B XXX XXX XXX
EV/Revenue 6.0x XXX 5.8x XXX XXX XXX
EV/EBITDA 19.3x XXX 17.2x XXX XXX XXX
EV/EBIT 29.5x XXX 26.4x XXX XXX XXX
EV/Gross Profit 10.2x XXX n/a XXX XXX XXX
P/E 44.1x XXX 38.5x XXX XXX XXX
EV/FCF 36.2x XXX 29.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vitrolife Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Vitrolife Margins & Growth Rates

Vitrolife's last 12 month revenue growth is 4%

Vitrolife's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Vitrolife's rule of 40 is -87% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vitrolife's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Vitrolife and other 15K+ public comps

Vitrolife Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 4% XXX 1% XXX XXX XXX
EBITDA Margin 31% XXX 34% XXX XXX XXX
EBITDA Growth 8% XXX n/a XXX XXX XXX
Rule of 40 -87% XXX 38% XXX XXX XXX
Bessemer Rule of X XXX XXX 41% XXX XXX XXX
Revenue per Employee XXX XXX $0.3M XXX XXX XXX
Opex per Employee XXX XXX $0.1M XXX XXX XXX
S&M Expenses to Revenue XXX XXX 21% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 3% XXX XXX XXX
Opex to Revenue XXX XXX 37% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vitrolife Public Comps

See public comps and valuation multiples for Medical Devices comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
SmartVest XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
Myomo XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vitrolife M&A and Investment Activity

Vitrolife acquired  XXX companies to date.

Last acquisition by Vitrolife was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vitrolife acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vitrolife

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Vitrolife

When was Vitrolife founded? Vitrolife was founded in 1994.
Where is Vitrolife headquartered? Vitrolife is headquartered in Sweden.
How many employees does Vitrolife have? As of today, Vitrolife has 1.1K+ employees.
Who is the CEO of Vitrolife? Vitrolife's CEO is Ms. Bronwyn Brophy.
Is Vitrolife publicy listed? Yes, Vitrolife is a public company listed on STO.
What is the stock symbol of Vitrolife? Vitrolife trades under VITR ticker.
When did Vitrolife go public? Vitrolife went public in 2001.
Who are competitors of Vitrolife? Similar companies to Vitrolife include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem.
What is the current market cap of Vitrolife? Vitrolife's current market cap is $2.1B
What is the current revenue of Vitrolife? Vitrolife's last 12 months revenue is $367M.
What is the current revenue growth of Vitrolife? Vitrolife revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Vitrolife? Current revenue multiple of Vitrolife is 6.0x.
Is Vitrolife profitable? Yes, Vitrolife is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Vitrolife? Vitrolife's last 12 months EBITDA is $114M.
What is Vitrolife's EBITDA margin? Vitrolife's last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Vitrolife? Current EBITDA multiple of Vitrolife is 19.3x.
What is the current FCF of Vitrolife? Vitrolife's last 12 months FCF is $60.5M.
What is Vitrolife's FCF margin? Vitrolife's last 12 months FCF margin is 17%.
What is the current EV/FCF multiple of Vitrolife? Current FCF multiple of Vitrolife is 36.2x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.